Nephroblastoma Treatment Market Research Report - Global Forecast till 2027

Nephroblastoma Treatment Market Research Report– By Types (Favorable Histology, Unfavorable Histology (Anaplastic Wilms Tumor)), By Drugs (Dactinomycin, Doxorubicin, Vincristine, Cyclophosphamide, Etoposide), By Diagnosis (Ultrasound, Ct, Mri), By Treatment, By Distribution Channel, By End User– Global Forecast Till 2027

ID: MRFR/HC/3791-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Nephroblastoma also known as Wilms’ Tumor is a rare type of malignant kidney cancer generally found in children mostly under the age of seven. It occurs during the embryonic stage, where it develops from immature kidney cells which are involved in the child’s kidney while they are present in the womb. At the time of birth, the cells usually disappear, but in some cases primitive kidney cell clusters can persist, giving way to this condition. This condition is characterised by abnormalities of the genitals known as hemihypertrophy. According to NCBI, nephroblastoma appears as childhood renal tumor, accounting for about 6% of all pediatric malignancies. It predominantly affects children less than five years of age, with 90% of cases diagnosed before age of three years.


Over the last 25 years, the treatment of nephroblastoma has made great progress. Surgery, chemotherapy and sometimes radiation therapy is used for the treatment of nephroblastoma. Treatments vary according to the stage of cancer. Nephroblastoma treatment market is growing due to the increasing incidence of new-born, technological advancement in therapies is acting as a driving force for the global nephroblastoma treatment market.


Furthermore, macro-economic factors such as increasing expenditure on research and development to develop novel therapies for nephroblastoma will drive this market in forecast period. On the other hand, lack of skilled healthcare professionals, rich experience in using these advanced technologies, high cost associated with the diagnosis and treatment procedure are expected to act as a restrains to the nephroblastoma treatment market.


The global nephroblastoma treatment market is expected to grow at a CAGR of approximately 7.1% during the forecast period 2017-2023.


Intended Audience



  • Nephroblastoma Drug Suppliers

  • Nephroblastoma Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Segmentation


The nephroblastoma treatment is segmented on the basis of types, drugs, diagnosis, treatment, distribution channel, and end-users.


On the basis of the types, the market is segmented into favorable histology, unfavorable histology (anaplastic Wilms tumor).


On the basis of the drugs, the market is segmented into dactinomycin (cosmegen), doxorubicin (adriamycin), vincristine (vincasar pfs, oncovin), cyclophosphamide (cytoxan, neosar), etoposide (toposar, vepesid), irinotecan (camptosar) and others.


On the basis of the diagnosis, the market is segmented into ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI), chest x-ray, bone scan, lab tests and others.


On the basis of the treatment, the market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery is classified into radical nephrectomy, partial nephrectomy (nephron-sparing surgery) and others.


On the basis of the distribution channel, the market is segmented into hospital pharmacies, e-commerce, drug stores, retail pharmacy, and others.


On the basis of the end-user, the market is segmented into hospitals, cancer centers, surgical centers and ambulatory surgical center.
Key Players


Some of key the players in the global nephroblastoma treatment market are Bayer HealthCare LLC (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.),  Sanofi Pasteur Inc. (U.S.),  Merck & Co. Inc. (U.S.),  MediLexicon International Ltd (U.S.), Bristol-Myers Squibb Company (U.S.), Apotex Inc. (U.S.), and others.


Research Methodology
Nephroblastoma Treatment Market


Sources: Annual reports, Press release, White paper, and Company presentation


Regional Analysis


The global nephroblastoma treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.


The Americas is projected to hold the largest share of the global nephroblastoma treatment market. Analyzing the present scenario North America dominates the global market for nephroblastoma followed by Europe due to the high incidence rate of nephroblastoma. According to the American Society of Cancer in 2015, about 500 new cases of nephroblastoma were diagnosed in the U.S.


Europe is expected to capture the second lead in this market in the coming five years owing to factors such as increasing demand for diagnostic solutions and treatment therapies for nephroblastoma, substantial technological advancements. The European nephroblastoma market is expected to have a tremendous growth during the forecast period


The market in the Asia Pacific is also expected to witness the fastest growth rate within the forecast period due to the high birth rate. As nephroblastoma is the most common renal malignancy in children. The five-year overall survival rates have dramatically improved to approximately 90% with multimodal therapy. The Middle East and Africa are also expected to show a healthy growth in the coming five years due to the disease prevalence, which is relatively more in the African countries while comparatively less in East Asia.



TABLE OF CONTENT


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Treatment Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Nephroblastoma Treatment Market, by Types

6.1 Introduction

6.2 Favorable histology

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Unfavorable histology

6.3.1 Market Estimates & Forecast, 2020-2027

Chapter 7. Global Nephroblastoma Treatment Market, by drug

7.1 Introduction

7.2 Dactinomycin (cosmegen)

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Doxorubicin (adriamycin)

7.3.1 Market Estimates & Forecast, 2020-2027

7.4 Vincristine (vincasar pfs, oncovin)

7.4.1 Market Estimates & Forecast, 2020-2027

7.5 Cyclophosphamide (cytoxan, neosar)

7.5.1 Market Estimates & Forecast, 2020-2027

7.6 Etoposide (toposar, vepesid)

7.6.1 Market Estimates & Forecast, 2020-2027

7.7 Irinotecan (camptosar)

7.7.1 Market Estimates & Forecast, 2020-2027

7.8 Others

Chapter 8. Global Nephroblastoma Treatment Market, by diagnosis

8.1 Introduction

8.2 Ultrasound

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Computerized tomography (CT)

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Magnetic resonance imaging (MRI)

8.4.1 Market Estimates & Forecast, 2020-2027

8.5 Chest x-ray

8.5.1 Market Estimates & Forecast, 2020-2027

8.6 Bone scan

8.6.1 Market Estimates & Forecast, 2020-2027

8.7 Lab tests

8.7.1 Market Estimates & Forecast, 2020-2027

8.8 Others

Chapter 9. Global Nephroblastoma Treatment Market, by treatment

9.1 Introduction

9.2 Surgery

9.2.1 Market Estimates & Forecast, 2020-2027

9.2.2 Radical nephrectomy

9.2.2.1 Market Estimates & Forecast, 2020-2027

9.2.3 Partial nephrectomy (nephron-sparing surgery)

9.2.3.1 Market Estimates & Forecast, 2020-2027

9.2.4 Others

9.3 Chemotherapy

9.3.1 Market Estimates & Forecast, 2020-2027

9.4 Radiation therapy

9.4.1 Market Estimates & Forecast, 2020-2027

9.5 Others

Chapter 10. Global Nephroblastoma Treatment Market, by Distribution channel

10.1 Introduction

10.2 Hospital pharmacies

10.2.1 Market Estimates & Forecast, 2020-2027

10.3 E-commerce

10.3.1 Market Estimates & Forecast, 2020-2027

10.4 Drug stores

10.4.1 Market Estimates & Forecast, 2020-2027

10.5 Retail pharmacy

10.5.1 Market Estimates & Forecast, 2020-2027

10.6 Others

Chapter 11. Global Nephroblastoma Treatment Market, by End User

11.1 Introduction

11.2 Hospitals

11.2.1 Market Estimates & Forecast, 2020-2027

11.3 Cancer centers

11.3.1 Market Estimates & Forecast, 2020-2027

11.4 Surgical centers

11.4.1 Market Estimates & Forecast, 2020-2027

11.5 Ambulatory surgical center

11.5.1 Market Estimates & Forecast, 2020-2027

Chapter. 12 Global Nephroblastoma Treatment Market, by Region

12.1 Introduction

12.2 Americas

12.2.1 North America

12.2.1.1 U.S.

12.2.1.1 Canada

12.2.2 South America

12.3 Europe

12.3.1 Western Europe

12.3.1.1 Germany

12.3.1.2 France

12.3.1.3 Italy

12.3.1.4 Spain

12.3.1.5 U.K

12.3.1.6 Rest of Western Europe

12.3.2 Eastern Europe

12.4 Asia Pacific

12.4.1 Japan

12.4.2 China

12.4.3 India

12.4.4 Australia

12.4.5 Republic of Korea

12.4.6 Rest of Asia Pacific

12.5 The Middle East & Africa

12.5.1 United Arab Emirates

12.5.2 Saudi Arabia

12.5.3 Rest of the Middle East & Africa

Chapter 13 Company Landscape

13.1 Introduction

13.2 Market Share Analysis

13.3 Key Development & Strategies

13.3.1 Key Developments

Chapter 14 Company Profiles

14.1 Bayer HealthCare LLC

14.1.1 Company Overview

14.1.2 Treatment Overview

14.1.3 Financials

14.1.4 SWOT Analysis

14.2 F. Hoffmann-La Roche Ltd

14.2.1 Company Overview

14.2.2 Treatment Overview

14.2.3 Financial Overview

14.2.4 Key Developments

14.2.5 SWOT Analysis

14.3 Pfizer Inc.

14.3.1 Company Overview

14.3.2 Treatment Overview

14.3.3 Financial Overview

14.3.4 Key Development

14.3.5 SWOT Analysis

14.4 Sanofi Pasteur Inc.

14.4.1 Company Overview

14.4.2 Treatment/Business Segment Overview

14.4.3 Financial Overview

14.4.4 Key Development

14.4.5 SWOT Analysis

14.5 Merck & Co. Inc.

14.5.1 Company Overview

14.5.2 Treatment Overview

14.5.3 Financial overview

14.5.4 Key Developments

14.6 MediLexicon International Ltd

14.6.1 Company Overview

14.6.2 Treatment Overview

14.6.3 Financial Overview

14.6.4 Key Developments

14.7 Bristol-Myers Squibb Company

14.7.1 Overview

14.7.2 Treatment Overview

14.7.3 Financials

14.7.4 Key Developments

14.7.5 SWOT Analysis

14.8 Apotex Inc.

14.8.1 Company Overview

14.8.2 Treatment/Business Segment Overview

14.8.3 Financial Overview

14.8.4 Key Development

14.8.5 SWOT Analysis

14.9 Others

Chapter 15 MRFR Conclusion

15.1 Key Findings

15.1.1 From CEO’s View Point

15.1.2 Unmet Needs of the Market

15.2 Key Companies to Watch

15.3 Prediction of Pharmaceutical industry

Chapter 16 Appendix

LIST OF TABLES


Table 1 Nephroblastoma treatment Industry Synopsis, 2020-2027

Table 2 Nephroblastoma treatment Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Nephroblastoma treatment Market by Region, 2020-2027, (USD Million)

Table 4 Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)

Table 5 Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)

Table 6 Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 7 Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)

Table 8 Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)

Table 9 Nephroblastoma treatment Market by End Users, 2020-2027, (USD Million)

Table 10 North America Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)

Table 11 North America Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)

Table 12 North America Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 13 North America Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)

Table 14 North America Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)

Table 15 North America Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)

Table 16 US Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)

Table 17 US Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)

Table 18 US Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 19 US Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)

Table 20 US Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)

Table 21 US Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)

Table 22 Canada Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)

Table 23 Canada Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)

Table 24 Canada Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 25 Canada Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)

Table 26 Canada Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)

Table 27 Canada Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)

Table 28 South America Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)

Table 29 South America Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)

Table 30 South America Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 31 South America Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)

Table 32 South America Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)

Table 33 South America Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)

Table 34 Europe Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)

Table 35 Europe Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)

Table 36 Europe Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 37 Europe Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)

Table 38 Europe Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)

Table 39 Europe Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)

Table 40 Western Europe Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)

Table 41 Western Europe Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)

Table 42 Western Europe Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 43 Western Europe Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)

Table 44 Western Europe Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)

Table 45 Western Europe Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)

Table 46 Eastern Europe Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)

Table 47 Eastern Europe Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)

Table 48 Eastern Europe Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 49 Eastern Europe Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)

Table 50 Eastern Europe Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)

Table 51 Eastern Europe Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)

Table 52 Asia Pacific Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)

Table 53 Asia Pacific Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)

Table 54 Asia Pacific Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 55 Asia Pacific Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)

Table 56 Asia Pacific Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)

Table 57 Asia Pacific Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)

Table 58 The Middle East & Africa Nephroblastoma treatment Market by Type, 2020-2027, (USD Million)

Table 59 The Middle East & Africa Nephroblastoma treatment Market by Drugs, 2020-2027, (USD Million)

Table 60 The Middle East & Africa Nephroblastoma treatment Market by Diagnosis, 2020-2027, (USD Million)

Table 61 The Middle East & Africa Nephroblastoma treatment Market by Treatment, 2020-2027, (USD Million)

Table 62 The Middle East & Africa Nephroblastoma treatment Market by Distribution Channel, 2020-2027, (USD Million)

Table 63 The Middle East & Africa Nephroblastoma treatment Market by End User, 2020-2027, (USD Million)

LIST OF FIGURES


Figure 1 Research Process

Figure 2 Segmentation for Nephroblastoma treatment Market

Figure 3 Segmentation Market Dynamics for Nephroblastoma treatment Market

Figure 4 Global Nephroblastoma treatment Market Share, by Type 2020-2027

Figure 5 Global Nephroblastoma treatment Market Share, by Drugs 2020-2027

Figure 6 Global Nephroblastoma treatment Market Share, by Diagnosis, 2020-2027

Figure 7 Global Nephroblastoma treatment Market Share, by Treatment, 2020-2027

Figure 8 Global Nephroblastoma treatment Market Share, by Distribution Channel, 2020-2027

Figure 9 Global Nephroblastoma treatment Market Share, by End Users, 2020-2027

Figure 10 Global Nephroblastoma treatment Market Share, by Region, 2020-2027

Figure 11 North America Nephroblastoma treatment Market Share, by Country, 2020-2027

Figure 12 Europe Nephroblastoma treatment Market Share, by Country, 2020-2027

Figure 13 Asia Pacific Nephroblastoma treatment Market Share, by Country, 2020-2027

Figure 14 The Middle East & Africa Nephroblastoma treatment Market Share, by Country, 2020-2027

Figure 15 Global Nephroblastoma treatment Market: Company Share Analysis, 2020-2027 (%)

Figure 16 Bayer HealthCare LLC: Key Financials

Figure 17 Bayer HealthCare LLC: Segmental Revenue

Figure 18 Bayer HealthCare LLC: Geographical Revenue

Figure 19 F. Hoffmann-La Roche Ltd: Key Financials

Figure 20 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 21 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 22 Pfizer Inc.: Key Financials

Figure 23 Pfizer Inc.: Segmental Revenue

Figure 24 Pfizer Inc.: Geographical Revenue

Figure 25 Sanofi Pasteur Inc.: Key Financials

Figure 26 Sanofi Pasteur Inc.: Segmental Revenue

Figure 27 Sanofi Pasteur Inc.: Geographical Revenue

Figure 28 Merck & Co. Inc.: Key Financials

Figure 29 Merck & Co. Inc.: Segmental Revenue

Figure 31 Merck & Co. Inc.: Geographical Revenue

Figure 32 MediLexicon International Ltd: Key Financials

Figure 33 MediLexicon International Ltd: Segmental Revenue

Figure 34 MediLexicon International Ltd: Geographical Revenue

Figure 35 Bristol-Myers Squibb Company: Key Financials

Figure 36 Bristol-Myers Squibb Company: Segmental Revenue

Figure 37 Bristol-Myers Squibb Company: Geographical Revenue

Figure 38 Apotex Inc: Key Financials

Figure 39 Apotex Inc: Segmental Revenue

Figure 40 Apotex Inc: Geographical Revenue



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.